Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Part of paid clinical trials in Newark, Delaware.

Sponsor
Eli Lilly and Company
Study ID
NCT00207077
Phase
PHASE1
Status
Completed

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cetuximab + Erlotinib — DRUG
    IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.

Study Details

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Key Dates

First listed
Sep 21, 2005
Start date
Aug 31, 2005
Status verified
Oct 2015
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
33 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A

Primary Outcome Measure

Safety and efficacy of the combination of Tarceva and Erbitux

Locations (1)

FacilityCityStateZIPSite coordinators
Christiana Care Health Services, Inc.NewarkDelaware19718-

Find similar trials in Newark, DE

By research site
Christiana Care Health Services, Inc.· Newark, DE

Related Studies